Bio venture company IntoCell said on the 24th that it successfully completed the patient dosing stage in the phase 1 clinical trial of its antibody-drug conjugate (ADC) new drug candidate "ITC-6146RO."
ITC-6146RO is an ADC candidate that targets the B7-H3 protein, which is frequently expressed in various solid tumors. The agent is designed to selectively attack cancer cells by conjugating a cytotoxic payload (payload, a therapeutic substance carried by the antibody). B7-H3 is a protein that, unlike in normal cells, is frequently expressed in cancer cells and is considered a next-generation target antigen.
ITC-6146RO incorporates IntoCell's proprietary ADC platform technologies "OHPAS" and "PMT (selectivity enhancement technology)."
OHPAS is designed to maintain stability in the bloodstream while selectively releasing the drug within tumors. PMT is a technology that optimizes the physicochemical properties of the payload to improve activity efficiency.
The clinical trial is being conducted in a multicenter, open-label design and targets patients with solid tumors who did not respond to standard therapy or developed resistance. In the dose-escalation stage, the plan is to confirm the safety and tolerability of the candidate, determine the appropriate dose, and focus on evaluating its initial anticancer effect.
An IntoCell official said, "This first patient dosing is an important milestone in that our ADC platform has entered the actual clinical stage," adding, "Through phase 1, we will closely verify safety and initial efficacy and expand into global development."